Who are Actos (Pioglitazone)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): rosiglitazone maleate/metformin hydrochloride, IMP Pioglitozone, Rosiglitazone and Pegasys/Ribavirin, rosiglitazone-metformin, CSII, Metformin, Pioglitazone, Rosiglitazone XR.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/actos-pioglitazone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Actos (Pioglitazone) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Actos (Pioglitazone) (Actos (Pioglitazone)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thiazolidinediones. Area: Metabolic.

marketed Thiazolidinediones PPAR-γ Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Actos (Pioglitazone) (Actos (Pioglitazone)) — Taipei Veterans General Hospital, Taiwan. Actos (pioglitazone) is a thiazolidinedione that enhances insulin sensitivity in peripheral tissues, particularly in adipose tissue, skeletal muscle, and liver.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Actos (Pioglitazone) TARGET	Actos (Pioglitazone)	Taipei Veterans General Hospital, Taiwan	marketed	Thiazolidinediones	PPAR-γ
rosiglitazone maleate/metformin hydrochloride	rosiglitazone maleate/metformin hydrochloride	GlaxoSmithKline	marketed	Thiazolidinedione/Biguanide combination	PPAR-γ (rosiglitazone); Complex I of mitochondrial respiratory chain (metformin)
IMP Pioglitozone	IMP Pioglitozone	University of Nottingham	marketed	Thiazolidinedione (PPAR-γ agonist)	PPAR-γ (Peroxisome proliferator-activated receptor gamma)
Rosiglitazone and Pegasys/Ribavirin	Rosiglitazone and Pegasys/Ribavirin	Beth Israel Medical Center	marketed	Thiazolidinedione (rosiglitazone) combined with pegylated interferon alfa-2a and nucleoside analog (ribavirin)	PPAR-γ (rosiglitazone); Interferon-α receptor and HCV NS5B polymerase (pegasys/ribavirin)
rosiglitazone-metformin	rosiglitazone-metformin	GlaxoSmithKline	marketed	Thiazolidinedione + Biguanide combination	PPAR-γ (rosiglitazone component); Complex mitochondrial mechanism (metformin component)
CSII, Metformin, Pioglitazone	CSII, Metformin, Pioglitazone	Sun Yat-sen University	marketed	Insulin + biguanide + thiazolidinedione combination	Insulin receptor (CSII); AMPK/mitochondrial function (metformin); PPAR-γ (pioglitazone)
Rosiglitazone XR	Rosiglitazone XR	GlaxoSmithKline	marketed	Thiazolidinedione (PPAR-γ agonist)	PPAR-γ (Peroxisome proliferator-activated receptor gamma)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thiazolidinediones class)

Taipei Veterans General Hospital, Taiwan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Actos (Pioglitazone) — Competitive Intelligence Brief. https://druglandscape.com/ci/actos-pioglitazone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing